Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
May 28, 2024 07:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
May 22, 2024 18:21 ET
|
Foghorn Therapeutics, Inc.
Positions company to further leverage strength of platform and advance programs through multiple data readouts and clinical value inflection points Strengthens balance sheet with cash, cash...
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
May 20, 2024 07:58 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (“Foghorn”) (Nasdaq: FHTX) today announced the pricing of a registered direct offering of 12,743,039 shares of its common...
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
May 06, 2024 07:00 ET
|
Foghorn Therapeutics, Inc.
Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based differentiation...
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
April 16, 2024 07:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
April 09, 2024 16:30 ET
|
Foghorn Therapeutics, Inc.
First-in class BRM (SMARCA2) selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically; IND filing on track for Q2...
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
April 05, 2024 07:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
March 26, 2024 07:00 ET
|
Foghorn Therapeutics, Inc.
Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader...
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
March 07, 2024 07:00 ET
|
Foghorn Therapeutics, Inc.
• Dose escalation in FHD-286 combination study in AML continues to progress; clinical data anticipated in the second half of 2024 • FHD-909, a first-in-class BRM selective inhibitor, selected for...
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, Including the Selective Inhibitor of BRM, FHD-909
March 05, 2024 16:48 ET
|
Foghorn Therapeutics, Inc.
Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in multiple mouse models of NSCLC; IND filing planned in Q2 2024Oral...